Jefferies Starts Agenus Inc. (AGEN) at Buy; Sees 100% Upside
December 16, 2015 7:54 AM EST
Jefferies initiates coverage on Agenus Inc. with a Buy rating and a price target of $8.00.
Analyst Biren Amin commented,
"Agenus is developing a comprehensive Immuno-Oncology (IO) platform consisting of multiple checkpoints both fully owned and through partnerships and could be a leader in cancer vaccine development through the deployment of its QS-21 adjuvant which could increase the efficacy of cancer vaccines. AGEN is also partnered with Merck and Incyte across 9 novel IO programs totaling >$450M in milestones. Therefore, AGEN's $130M EV offers significant upside, in our view."
Learn my "Core and Explore" approach to investing
with "Kirk Lindstrom's Investment Letter"
Don't miss out! Subscribe Now
I have a very generous Refund Policy
so your risk is minimal
- Dec 10 6
Weekly Sentiment Charts - Was It A Bloody Gash Or A Cut?
- Nov 3 New Series I Bonds Offer Attractive Rates
- Oct 15 2016 Social Security COLA: Cost-of-Living Adjustment (COLA) for 2016
- Sept 2 Good News for Intel Stock - End of Inventory Correction